Ascension St. Vincent's Hospital
Carmel, Indiana, 46260, United States
Location contact
David Heimansohn, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07684313
TRIBLAZE is a prospective, observational, single-arm, multicenter study designed to collect real-world clinical outcomes in a minimum of 75 participants who will receive the Edwards Lifesciences TRIFORMIS RESILIA surgical tricuspid heart valve, Model 11300T.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Carmel, Indiana, 46260, United States
David Heimansohn, MD
PRINCIPAL_INVESTIGATOR
Subjects in the TRIBLAZE study will be enrolled at up to 15 sites in the United States. The population will be participants requiring replacement of their native or prosthetic tricuspid valve.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Surgical replacement of the tricuspid valve with the Edwards TRIFORMIS RESILIA heart valve
Time frame: 1 Year
Mean gradient is the average flow of blood through the tricuspid valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.
Time frame: 1 Year
Peak gradient is the maximum value measured of flow of blood through the tricuspid valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher valve is considered worse, and a lower value is considered better, but the value is dependent on the size and type of valve.
Time frame: 1 Year
Effective orifice area represents the cross-sectional area of the blood flow downstream of the tricuspid valve. Effective orifice area is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size and type of valve.
Time frame: 1 Year
Valvular regurgitation occurs when the valve in the heart does not close tightly, allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation, 1 = a trace of regurgitation, 2 = mild regurgitation, 3 = moderate regurgitation, and 4 represents severe regurgitation. Higher numbers on the scale show a worsening outcome.
Time frame: 1 Year
Right ventricular function is the heart's ability to pump deoxygenated blood through the pulmonary circulation into the lungs. Right ventricular function is assessed via echocardiography. It is assessed on a scale of: Normal, Mild dysfunction, Moderate dysfunction, Moderate-severe dysfunction, or Severe dysfunction.
Time frame: 1 Year
Paravalvular leak refers to blood flowing through a channel between the implanted artificial valve and the cardiac tissue as a result of inappropriate sealing. Paravalvular leak is evaluated by echocardiography over time. It is assessed on a scale from minimum of 0 to maximum of 4, where 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak. Higher numbers on the scale show a worsening outcome.
Time frame: Baseline and 1 Year
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a validated, disease-specific health status tool for patients with heart failure. It measures symptoms, physical and social limitations, and quality of life over the previous two weeks. Scores range from 0 to 100, where higher numbers indicate better health and fewer symptoms and lower numbers indicate wore health and more symptoms.
Time frame: Baseline, 1 month, 1-, 2-, 3-, 4-, and 5- Years follow-up
The New York Heart Association functional classification system relates symptoms to everyday activities and the patient's quality of life.
Class I. Patients with cardiac disease but without resulting limitation of physical activity.
Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.
Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort.
Symptoms of heart failure or anginal syndrome may be present even at rest.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Participants' freedom from all cause mortality. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Participants' freedom from cardiovascular mortality. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Participants' freedom from valve-related mortality. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Participants' freedom from a reoperation on their tricuspid valve. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Participants' freedom from valve-related pulmonary embolism. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Participants' freedom from valve-related valve thrombosis. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Participants' freedom from valve-related hemorrhage. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Participants' freedom from valve-related endocarditis. Time to events were estimated by Kaplan-Meier method.
Time frame: 1-, 2-, 3-, 4-, and 5- Years follow-up
Participants' freedom from tricuspid valve-related heart failure hospitalization. Time to events were estimated by Kaplan-Meier method.
Contact information is provided by the study sponsor or research team.
Edwards Lifesciences
Industry
Multi-center, Single-arm, Observational Study Assessing Real-world Safety and Performance of the TRIFORMIS RESILIA Tricuspid Valve for Surgical Tricuspid Valve Replacement (TRIBLAZE Study)
Acronym: TRIBLAZE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03142152
Cardiovascular Diseases, Functional Mitral Regurgitation
Gilbert, Arizona, United States
View Trial DetailsNCT06449469
Aortic Valve Disease, Aortic Valve Stenosis
Aarhus, Denmark
View Trial DetailsNCT02825134
Aortic Valve Disease, Aortic Valve Stenosis
Aarhus, Denmark
View Trial DetailsNCT02981953
Cardiac Valve Annuloplasty, Cardiovascular Diseases
Paris, France
View Trial Details